Industrial bioscience firm Amyris (Emeryville, California) announced on Monday that it has entered into its first product development and production agreement with DSM.
The agreement covers an undisclosed food and nutrition molecule for which DSM is a major market provider. DSM will fund technology development, and Amyris will scale and supply the ingredient in the long-term.
The agreement is expected to be the first of many such collaborations, Amyris says. In May, DSM made an initial equity investment in Amyris of $25 million for a shareholding of about 12%. Subject to certain conditions, DSM could invest an additional $25 million in the company within 90 days of the first tranche if approved by DSM’s board. As part of the deal, DSM and Amyris agreed to collaborate on a number of short- to medium-term product development and production opportunities using Amyris’s yeast-based strain engineering platform.
By Rebecca Coons
Source: Chemical Week
The investment enables the steam cracker to increase the share of renewable and recycled raw materials used in its (ethylene and propylene) production. The move supports the Borealis Strategy 2030 for a circular economy. The Porvoo investment program is expected to be completed in 2025.
Murray Auchincloss, bp’s CEO, said in a statement: “As I set out in February, BP’s destination from IOC [international oil company] to IEC [integrated energy company] is unchanged – and we need to deliver as a simpler, more focused, and higher-value company.
Founded in 1972, Tecnofilm has expanded its product portfolio over the years to offer a wider range of compounds and functional polymers for various industrial applications and technical articles. The company has patented several of its products.
